This latest order officially adds 174 substances to the NDSL. For companies manufacturing or importing chemical substances into Canada, this update provides a more streamlined regulatory environment.

Substances listed on the NDSL benefit from:

• Higher Volume Thresholds: Allowing for larger quantities to be handled before specific notification requirements are triggered.
• Streamlined Notifications: Providing a more direct and efficient path to compliance compared to substances not appearing on the list.

It is critical for stakeholders to remain aware of NDSL additions, as these changes can directly impact your notification strategy and timelines. Utilizing substances on this list often results in reduced administrative burden and faster processing for your chemical notifications.

If you need any assistance with these associated regulatory updates, our team is here to assist you.

The post 174 Substances Added to the Non-Domestic Substances List (NDSL) appeared first on Focal Point.

​Previously, navigating requirements could be complex due to the overlap with prescription drug content. The new landing page serves as a distinct resource, ensuring that NPD requirements are easily accessible and separated from other drug categories.

​Key Highlights of the New Portal

• ​The page provides comprehensive guidance covering the full product lifecycle, ranging from initial authorization to essential post-market activities.
• ​Both the Labelling Standards and Category IV Monograph pages have been refreshed with updated links and current information to ensure accuracy in submissions.
• The NNHPD has committed to updating this landing page regularly as new regulatory content and guidance documents become available.

​How We Can Help

​Navigating departmental updates and ensuring compliance can be a rigorous process. If you need any assistance with your NPD registrations, comprehensive labeling reviews, or interpreting how these new guidelines impact your specific product portfolio, we are ready to provide the necessary support.

The post NNHPD Launches Dedicated Landing Page for Non-prescription Drugs appeared first on Focal Point.

Phase 1 reporting remains mandatory. Producers of packaging, electronics and electrical equipment, and single-use plastics destined for the residential waste stream must continue to submit required data.

Additionally, ECCC has announced plans to introduce a new reporting notice for 2027-2029 and is seeking stakeholder input.

For more information, contact us.

The post Federal Plastics Registry: Reporting Deadlines Updated appeared first on Focal Point.

If you have questions or would like guidance on how this change may impact your registrations, please reach out to our team.

The post FDA Issues Final rule on Nation Drug Code (NDC) format appeared first on Focal Point.

Should you identify these two ingredients in your formulations and would like further information on next steps, please contact us.

The post New SNAc provisions added for two substances on Canada’s DSL appeared first on Focal Point.

For applications received on or after December 15, 2025, priority will be based on the application’s date of receipt, as attestation questions are now integrated directly into the PLA form. This process aligns with the NHP Management of Applications Policy and ensures a fair, transparent, and consistent review process while managing high application volumes. Applicants must ensure that all attestations in the PLA form are accurate, complete, and meet eligibility requirements.

Give us a call to understand more about NNHPD operations.

The post NNHPD clarifies review prioritization for NHP licence applications appeared first on Focal Point.

The NNHPD is contacting affected licence holders and requesting removal of these carbomers from formulations. Note that any for drug products containing these carbomer ingredients, Health Canada is also reaching out to DIN holders requesting removal of these carbomers from formulations. If you have questions or would like guidance on how this change may affect your products, please reach out to our team.

The post NNHPD Updates NHPID entries due to Benzene risk appeared first on Focal Point.

The update aims to reduce duplicate reporting and regulatory burden. Under the revised guidance, MAHs are not required to routinely monitor the Canada Vigilance Online database or Health Product InfoWatch for Individual Case Safety Report (ICSR) obligations. However, MAHs must still report serious, unexpected adverse reactions occurring outside Canada, including those identified through foreign regulatory authority databases. If it cannot be confirmed whether the product belongs to the MAH, the report should be submitted to Health Canada with that limitation noted.

The updated guidance took effect on February 19, 2026. If you have questions or would like guidance on how this change may impact your processes, please reach out to our team.

The post Health Canada updates guidance on Adverse Reaction Reporting appeared first on Focal Point.

In addition, as of April 01, 2026, all Class II, III and IV medical device applications and amendments must be submitted electronically through the Regulatory Enrolment Process via the Common Electronic Submissions Gateway. Email submissions will no longer be accepted.

Health Canada has also implemented a new Terms and Conditions framework for device licenses, strengthening post-market oversight and adopted the International Medical Device Regulators Forum Table of Contents format to align with global standards. These changes aim to streamline submissions and improve regulatory efficiency.

If you need additional information or guidance on navigating these new processes, please reach out to us.

The post Health Canada modernizes Medical Device Submission Requirements appeared first on Focal Point.

This delay is intended to improve the efficiency of the system and allow organizations more time to collect high-quality, consistent data. ECCC plans to streamline and optimize the reporting requirements before these phases are implemented.

What You Need to Know:

While Phases 2 and 3 are on hold, Phase 1 reporting requirements remain in effect.

Organizations must continue to report Phase 1 data for the 2024, 2025, and 2026 calendar years, as originally outlined in the Notice with respect to reporting of plastic resins and certain plastic products.

Who Must Still Report?

Reporting obligations continue for producers of:

Packaging, Electronics and electrical equipment, Single-use and disposable plastics destined for the residential waste stream.

Timeline and Next Steps:

ECCC has outlined the following schedule for upcoming regulatory notices:

Summer 2026: A new Notice will be published to establish reporting requirements for the 2027, 2028, and 2029 calendar years.

Winter 2026: A Notice of Intent will be published in the Canada Gazette to formally communicate the intentions to delay Phases 2 and 3.

Stakeholders will have opportunities throughout 2026 to engage with ECCC and provide feedback on changes to the Registry. Our team will continue to monitor these developments and share details on engagement sessions as they become available.

The post Federal Plastics Registry Reporting Delayed for Phases 2 & 3 appeared first on Focal Point.